Literature DB >> 7809838

Triglyceride-rich lipoproteins improve survival when given after endotoxin in rats.

T E Read1, C Grunfeld, Z Kumwenda, M C Calhoun, J P Kane, K R Feingold, J H Rapp.   

Abstract

BACKGROUND: Triglyceride-rich lipoproteins have been shown to bind bacterial endotoxin and inhibit its activity in vitro and to protect animals from death when administered before a lethal injection of endotoxin. We now demonstrate that triglyceride-rich lipoproteins can neutralize the toxic effects of endotoxin already in circulation.
METHODS: Rats were infused with a lethal dose of endotoxin, followed at various time intervals by an infusion of either mesenteric lymph containing nascent chylomicrons (1 gm chylomicron triglyceride/kg) or an equal volume of normal saline solution. Survival was measured at 48 hours. The experiment was then repeated, substituting the synthetic triglyceride-rich lipid emulsion (1 gm/kg) for chylomicrons. We also measured the clearance and tissue distribution of radioiodinated endotoxin in rats treated subsequently with chylomicrons or saline solution.
RESULTS: Chylomicron infusions significantly improved survival when given up to 30 minutes after a lethal dose of endotoxin (p < 0.05). Chylomicrons accelerated endotoxin clearance from the blood and increased endotoxin uptake by the liver. The synthetic triglyceride-rich lipid emulsion significantly improved survival when given up to 15 minutes after a lethal dose of endotoxin (p < 0.05).
CONCLUSIONS: Triglyceride-rich lipoproteins and synthetic triglyceride-rich lipid emulsions significantly improve survival of rats when given after a lethal dose of endotoxin. Lipoprotein treatment accelerates endotoxin clearance to the liver, which may account for the observed protection. These data suggest a possible therapeutic role for triglyceride-rich lipoproteins or synthetic lipid emulsions in the treatment of the endotoxemia of gram-negative sepsis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7809838     DOI: 10.1016/s0039-6060(05)80231-4

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Effect of hypertriglyceridemia on endotoxin responsiveness in humans.

Authors:  T van der Poll; C C Braxton; S M Coyle; M A Boermeester; J C Wang; P M Jansen; W J Montegut; S E Calvano; C E Hack; S F Lowry
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 2.  NKT cells in sepsis.

Authors:  Briana Leung; Hobart W Harris
Journal:  Clin Dev Immunol       Date:  2010-10-04

Review 3.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

4.  LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction.

Authors:  A C Vreugdenhil; A M Snoek; C van 't Veer; J W Greve; W A Buurman
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

5.  Enteral administration of high-fat nutrition before and directly after hemorrhagic shock reduces endotoxemia and bacterial translocation.

Authors:  Misha D P Luyer; Jan A Jacobs; Anita C E Vreugdenhil; M'hamed Hadfoune; Cornelis H C Dejong; Wim A Buurman; Jan Willem M Greve
Journal:  Ann Surg       Date:  2004-02       Impact factor: 12.969

6.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Not Induced in Artificial Human Inflammation and Is Not Correlated with Inflammatory Response.

Authors:  Matthias Wolfgang Heinzl; Michael Resl; Carmen Klammer; Margot Egger; Benjamin Dieplinger; Martin Clodi
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

7.  Presentation matters: Impact of association of amphiphilic LPS with serum carrier proteins on innate immune signaling.

Authors:  Loreen R Stromberg; Heather M Mendez; Jessica Z Kubicek-Sutherland; Steven W Graves; Nicolas W Hengartner; Harshini Mukundan
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.